Eran Broshy

CIK: 0001256230

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (41.7%)

Position reduction

Option Exercises (M)4 (33.3%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CERT

Certara, Inc.

Director

TBPH

Theravance Biopharma, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

CERT
Certara, Inc.
May 14, 2026
Award(A)
Restricted Stock Units
Direct
33.2K shares-
CERT
Certara, Inc.
May 14, 2026
Exercise(M)
Direct
15.8K shares-
TBPH
Theravance Biopharma, Inc.
Nov 26, 2025
Sale(S)
Direct
14K shares at avg. $20.00$280K
TBPH
Theravance Biopharma, Inc.
Nov 26, 2025
Exercise(M)
Share Option (Right to Buy)
Direct
14K shares at avg. $10.15-
TBPH
Theravance Biopharma, Inc.
Nov 26, 2025
Sale(S)
Direct
15.5K shares at avg. $20.00$310K
TBPH
Theravance Biopharma, Inc.
Nov 11, 2025
Sale(S)
Direct
15.5K shares at avg. $17.00$264K
TBPH
Theravance Biopharma, Inc.
Nov 11, 2025
Sale(S)
Direct
14K shares at avg. $18.50$259K
TBPH
Theravance Biopharma, Inc.
Nov 11, 2025
Sale(S)
Direct
15.5K shares at avg. $18.50$287K
TBPH
Theravance Biopharma, Inc.
Nov 11, 2025
Exercise(M)
Share Option (Right to Buy)
Direct
14K shares at avg. $10.15-
CERT
Certara, Inc.
May 21, 2025
Award(A)
Restricted Stock Units
Direct
15.8K shares-
CERT
Certara, Inc.
May 21, 2025
Exercise(M)
Direct
11.9K shares-
TBPH
Theravance Biopharma, Inc.
May 19, 2025
Award(A)
Direct
10.6K shares-

		Type	Shares	Price		Ownership
May 14, 2026	CERT Certara, Inc.	Award(A) Restricted Stock Units	33,222	-	-	Direct
May 14, 2026	CERT Certara, Inc.	Exercise(M)	15,757	-	$0	Direct
Nov 26, 2025	TBPH Theravance Biopharma, Inc.	Sale(S)	14,000	$20.00	$280,000	Direct
Nov 26, 2025	TBPH Theravance Biopharma, Inc.	Exercise(M) Share Option (Right to Buy)	14,000	$10.15	-	Direct
Nov 26, 2025	TBPH Theravance Biopharma, Inc.	Sale(S)	15,501	$20.00	$310,020	Direct
Nov 11, 2025	TBPH Theravance Biopharma, Inc.	Sale(S)	15,500	$17.00	$263,500	Direct
Nov 11, 2025	TBPH Theravance Biopharma, Inc.	Sale(S)	14,000	$18.50	$259,000	Direct
Nov 11, 2025	TBPH Theravance Biopharma, Inc.	Sale(S)	15,500	$18.50	$286,750	Direct
Nov 11, 2025	TBPH Theravance Biopharma, Inc.	Exercise(M) Share Option (Right to Buy)	14,000	$10.15	-	Direct
May 21, 2025	CERT Certara, Inc.	Award(A) Restricted Stock Units	15,757	-	-	Direct
May 21, 2025	CERT Certara, Inc.	Exercise(M)	11,928	-	-	Direct
May 19, 2025	TBPH Theravance Biopharma, Inc.	Award(A)	10,649	-	-	Direct

1-12 of 12 transactions

About BROSHY ERAN

BROSHY ERAN (SEC CIK 0001256230) files insider reports with the SEC as Director of Certara, Inc. (CERT) and Director of Theravance Biopharma, Inc. (TBPH).

Signal8 holds 6 ownership filings by BROSHY ERAN, all Form 4s, filed between May 21, 2025 and May 15, 2026. Those filings report 12 transactions, from May 19, 2025 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on BROSHY ERAN's filings is in RADNOR, PA.

Recent filings by BROSHY ERAN

May 14, 2026: Grant or award of CERT derivative securities (Form 4, code A).
May 14, 2026: Option exercise of CERT shares (Form 4, code M).
Nov 26, 2025: Open-market sale of TBPH shares (Form 4, code S).
Nov 26, 2025: Option exercise of TBPH derivative securities (Form 4, code M).
Nov 26, 2025: Open-market sale of TBPH shares (Form 4, code S).

Other insiders filing for Certara, Inc. (CERT)

Mohammed Faiz, Interim CFO
Anhalt Rona, Chief Human Resources Officer
Corcoran Daniel, SVP and General Counsel
Collins Cynthia, Director
Reynders John V W, Director
Bedi Arjun, Director

How to read Form 4 transaction codes